Widmer covers the sterility concerns behind the recall of some compounded GLP-1 injections and what patients with affected medication should do.
Recap by typeshit. Full story at Fox News.
The actor backed Ozempic in an interview while saying exercise has no shortcut. Doctors break down whether his advice holds up.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
KMOV shares an InvestigateTV+ segment on the weight loss drug trend and what your insurance plan may or may not pay for. Details are in the full report.
Talker Research polled 2,000 Americans for aesthetics company Revance. Of 1,402 GLP-1 users, over 24% reported a new identity shift after starting the drugs.
Loading…